Navigation Links
AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II
Date:4/23/2010

VIENNA, April 23, 2010 /PRNewswire/ -- AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

The prospective Alzheimer's vaccine AD02 by AFFiRiS AG will with immediate effect be used in a multicentre phase II clinical study in Austria and five other European countries. Clinical centres in Germany, France, the Czech Republic, Slovakia and Croatia are taking part in the study. A total of 420 patients will be recruited. Interested parties can find further information about the study on the homepage http://www.affiris.com. There is also a link to study registration via a trustee. You can also phone +43-512-56-73-73-0 (reference "Alzheimerstudie") please ask Ms Weiss.

During the past year the safety and tolerability of the vaccine has been confirmed; now the focus is on its efficacy. With regard to this, CEO and co-founder of the company Dr Walter Schmidt said: "Last year AD02, along with our second prospective Alzheimer's vaccine AD01, was primarily tested in terms of its safety and tolerability. Those primary endpoints have been met by vaccine formulations. The decision to nominate AD02 for phase II testing study is based on currently still confidential results of the interim analysis of the secondary endpoints of the preceding phase I studies".

Attractive Product Pipeline - Clear Priorities

The other reason for deciding to accelerate the progress of AD02 is the company's principle to set clear priorities in respect of its broad product pipeline. The pipeline also comprises vaccines for treating atherosclerosis, hypertension and three other indications, which are currently still confidential. In addition, AFFiRiS AG announced only a few weeks ago that a prospective vaccine for the treatment of Parkinson's disease will start phase I clinical studies at the beginning of 2011.

With regard to the extent of the development pipeline CSO Dr. Frank Mattner stated: "Even before the start of the company's first phase II study we were able to build up a very broad product pipeline. This success is based on two components: our AFFITOME(R) technology and our solid financial basis. The AFFITOME(R) technology is increasingly proving itself to be more than an ideal platform technology for our product developments. It provides innovative solutions for the therapeutic treatment of chronic diseases with unmet medical need and opens up attractive markets for us. Our investors, the MIG Fonds, had already recognised this potential four years ago. In this way they assured us of early and substantial financing, which has contributed decisively to the rapid and successful progress of our development projects".

Strategy with Success

The first successes of this business strategy came in October 2008 when GlaxoSmithKline (GSK) Biologicals acquired the licence to the rights to the Alzheimer's vaccines in a milestone deal with a value of up to EUR 430 million. Two payments totalling EUR 32.5 million have already been triggered. AFFiRiS AG continues to hold all rights on the AFFITOME(R) technology for other indications. In summary, the AFFITOME(R) technology delivers short peptides which functionally mimic highly-specific original native structures that are the key targets for treatment of chronic diseases. Based on these peptides, vaccines can be generated which induce antibodies targeting pathological variants of human proteins, but leaving parental "healthy" structures untouched.

About AFFiRiS AG (date April 2010):

On the basis of the company's own patents, AFFiRiS develops tailor-made peptide vaccines against Alzheimer's disease, atherosclerosis, Parkinson's disease hypertension and four other conditions with an urgent medical requirement and attractive market volumes. Alzheimer's is currently the most advanced project, with two potential products having just completed the phase I clinical studies. In October 2008 GlaxoSmithKline Biologicals became the licence partner for the Alzheimer's vaccine. The contract envisages (milestone-dependent) payments of up to EUR 430 million. A payment of EUR 10 million was triggered in October 2009 by the positive completion of two clinical phase I studies. At present AFFiRiS has 70 highly qualified employees working at the St. Marx campus in Vienna, Austria ( http://www.affiris.com).

    Contact AFFiRiS AG:
    Mag. Agnes Meyer
    Karl-Farkas-Gasse 22
    1030 Vienna
    T +43-1-798-15-75 - 390
    E agnes.meyer@affiris.com
    W http://www.affiris.com

    Copy Editing & Distribution:
    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    T +43-1-505-70-44
    E contact@prd.at
    W http://www.prd.at



'/>"/>
SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
2. AFFiRiS Begins Development of a Parkinsons Vaccine
3. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
4. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
5. Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
6. HIV Vaccine Strategy Expands Immune Responses
7. AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
8. President of Pfizer Vaccines, Mark Swindell, Named as the Healthcare Businesswomens Associations 2010 Honorable Mentor
9. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
10. MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention to ... close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX Corp. ... Pharmaceuticals Inc. (NASDAQ: REGN ). According to a report ... 20 th , 2017, down on the day by about 0.5%. ... at: ...
(Date:1/23/2017)... -- A new Transparency Market Research report states that ... US$0.53 bn in 2013 and is predicted to touch US$2.38 bn ... and 2022. The title of the report is "Non-invasive Prenatal Testing ... and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to as non-invasive ...
(Date:1/23/2017)... global  anxiety disorders and depression treatment market  is expected to reach a value ... anticipated to drive the market growth in the coming years. Increasing adoption of ... recent years. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected ... her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published ... , Sharon shares that she started her spiritual journey later in life, but mentions, ...
(Date:1/24/2017)... ... 24, 2017 , ... Attention women who want bigger breasts ... autologous fat grafting—taking one’s own fat and putting it in other body part—is ... Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser Center, ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... The January ... features a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known ... distress and interpersonal difficulties while experiencing an increased sense of purpose both during and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The National Council ... for drug and alcohol awareness, have worked with communities to designate the last full ... January 23-29, 2017, the theme is “Shatter the Myths.” As a community, we ...
(Date:1/23/2017)... Jupiter Florida (PRWEB) , ... January 23, 2017 ... ... airing of the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to ... about the technology behind SmartCap, which was founded in 2008 to address the ...
Breaking Medicine News(10 mins):